Read by QxMD icon Read

hematopoeitic stem cell

Adrienne Alise Phillips
No abstract text is available yet for this article.
October 27, 2016: Leukemia & Lymphoma
Chen-Hua Yan, Yu Wang, Jing-Zhi Wang, Yu-Hong Chen, Yao Chen, Feng-Rong Wang, Yu-Qian Sun, Xiao-Dong Mo, Wei Han, Huan Chen, Xiao-Hui Zhang, Lan-Ping Xu, Kai-Yan Liu, Xiao-Jun Huang
BACKGROUND: Persons with acute leukemia relapsing after allotransplant and who respond to anti-leukemia interventions are at high risk of a second relapse. We studied the impact of minimal residual disease (MRD)- and graft-vs.-host disease (GvHD)-guided multiple consolidation chemotherapy and donor lymphocyte infusions (DLIs) to prevent second relapse in patients with acute leukemia relapsing post-transplant and who achieved complete remission after induction chemotherapy and DLI. METHODS: Forty-seven subjects with acute leukemia relapsing after an allotransplant and who achieved complete remission after post-relapse induction chemotherapy and DLI were eligible...
September 15, 2016: Journal of Hematology & Oncology
Greg D Whitehill, Shoba Amarnath, Pawel Muranski, Keyvan Keyvanfar, Minoo Battiwalla, Austin J Barrett, Dhanalakshmi Chinnassamy
Selective depletion (SD) of alloreactive T cells from allogeneic hematopoeitic stem cell transplants to prevent graft-versus-host disease (GVHD) without compromising immune reconstitution and antitumor responses remains a challenge. Here, we demonstrate a novel SD strategy whereby alloreacting T cells are efficiently deleted ex vivo with adenosine. SD was achieved in human leukocyte antigen (HLA) mismatched cocultures by multiple exposures to 2 mmol/l adenosine over 7 days. Adenosine depleted greater than to 90% of alloproliferating T cells in mismatched, haploidentical, and matched sibling pairs while conserving response to third-party antigens...
September 2016: Molecular Therapy: the Journal of the American Society of Gene Therapy
Mohammad El-Darouti, Marwa Fawzy, Iman Amin, Rania Abdel Hay, Rehab Hegazy, Hala Gabr, Zeinab El Maadawi
Patients with dystrophic epidermolysis bullosa (DEB) have mutations in type VII collagen gene. Type VII collagen is synthesized by keratinocytes and fibroblasts. Based on the ability of bone marrow non-hematopoeitic stem cells (NHBMSC) to develop into fibroblasts, we decided to investigate the use of NHBMSC in the treatment of recessive DEB (RDEB). This study included fourteen patients with RDEB; the first seven of them were given cyclosporine after the infusion of NHBMSC. As cyclosporine has been used for the treatment of RDEB we decided not to use cyclosporine for the second group of seven patients...
March 2016: Dermatologic Therapy
Arnaud G L'Huillier, Deepali Kumar
The Solid Organ Transplantation (SOT) and Haematopoietic Stem Cell Transplantation (HSCT) population is continuously increasing as a result of broader indications for transplant and improved survival. Infectious diseases, including vaccine-preventable diseases, are a significant threat for this population, primarily after but also prior to transplantation. As a consequence, clinicians must ensure that patients are optimally immunized before transplantation, to provide the best protection during the early post-transplantation period, when immunosuppression is the strongest and vaccine responses are poor...
2015: Human Vaccines & Immunotherapeutics
Igor Stepanovich Bryukhovetskiy, Polina Viktorovna Mischenko, Elena Vadimovna Tolok, Sergei Victorovich Zaitcev, Yuri Stepanovich Khotimchenko, Andrei Stepanovich Bryukhovetskiy
Multiform glioblastoma is the most common primary, highly invasive, malignant tumor of the central nervous system, with an extremely poor prognosis. The median survival of patients following surgical resection, radiation therapy and chemotherapy does not exceed 12-15 months and thus, novel approaches for the treatment of the disease are required. The phenomenon of the directed migration of stem cells in tumor tissue presents a novel approach for the development of technologies that facilitate the targeted delivery of drugs and other therapeutic agents to the tumor foci...
April 2015: Oncology Letters
Priya Marwah, Rajpreet Soni, Lawrence Faulkner, Mohammed El Missiry, Cornelio Uderzo
Transplant associated thrombotic microangiopathy is a severe complication of Hematopoeitic stem cell transplantation. Although there is agreement in terms of diagnostic criteria, treatment options are not clarified yet. We present a patient aged 2.6 years who developed transplant associated thrombotic microangiopathy after allogeneic bone marrow transplantation and to discuss both risk factors and possible spontaneous remission of transplant associated thrombotic microangiopathy.
September 2014: Indian Journal of Hematology & Blood Transfusion
Melhem Solh
Hematopoeitic cell transplantation is established as a curative treatment for patients w acute myelogenous leukemia. Haploidentical family donor and umbilical cord blood (UCB) are alternative sources of stem cells for patients lacking a matched sibling or unrelated donor. The early challenges of transplant complications related to poor engraftment and graft-vs-host disease have been overcome with new strategies such as using 2 units and increased cell dose in UCB and T-cell depletion and post transplantation cyclophosphamide in haploidentical transplantation...
September 26, 2014: World Journal of Stem Cells
Sanjeev Kumar Sharma, Suman Kumar, Narendra Agrawal, Lavleen Singh, Anjan Mukherjee, Tulika Seth, Pravas Mishra, Sandeep Mathur, Lalit Dar, Manoranjan Mahapatra
INTRODUCTION: There is a high prevalence of cytomegalovirus (CMV) seropositivity in developing countries. An apparent risk of CMV reactivation increases following hematopoeitic stem cell transplantation. With effective surveillance and timely treatment using anti-viral therapy, morbidity and mortality associated with CMV reactivation can be reduced. OBJECTIVES: To evaluate the incidence and morbidity associated with CMV reactivation following hematopoeitic stem cell transplantation...
December 15, 2013: Journal of Infection in Developing Countries
Owais Khawaja, Mohammad Khalil, Omar Zmeili, Ayman O Soubani
OBJECTIVE: Describe the major discrepancies between the clinical and postmortem findings in critically ill cancer patients admitted to the medical intensive care unit (MICU). MATERIALS AND METHODS: Retrospectively review of the medical records of all cancer patients who were admitted to the MICU and underwent postmortem examination over 6 year period. The records were reviewed for demographics, Acute Physiology and Chronic Health Evaluation (APACHE) II score, clinical cause of death, and postmortem findings...
July 2013: Avicenna Journal of Medicine
Rudolph Kirk R Schultz, Kevin Scott Baker, Jaap J Boelens, Catherine M Bollard, R Maarten Egeler, Mort Cowan, Ruth Ladenstein, Arjan Lankester, Franco Locatelli, Anita Lawitschka, John E Levine, Mignon Loh, Eneida Nemecek, Charlotte Niemeyer, Vinod K Prasad, Vanderson Rocha, Shalini Shenoy, Brigitte Strahm, Paul Veys, Donna Wall, Peter Bader, Stephan A Grupp, Michael A Pulsipher, Christina Peters
More than 20% of allogeneic hematopoietic cell transplantations (HCTs) are performed in children and adolescents at a large number of relatively small centers. Unlike adults, at least one-third of HCTs in children are performed for rare, nonmalignant indications. Clinical trials to improve HCT outcomes in children have been limited by small numbers and these pediatric-specific features. The need for a larger number of pediatric HCT centers to participate in trials has led to the involvement of international collaborative groups...
September 2013: Biology of Blood and Marrow Transplantation
Ivy A W Ho, Paula Y P Lam
Human bone marrow is a reservoir containing cells with different self-renewal capabilities, such as mesenchymal stem cells (MSC) and hematopoeitic stem cells (HSC). MSC in particular have been increasingly used in preclinical and clinical treatment of tissue regenerative disorder. Understanding the molecular mechanisms underlying MSC homing and mobilization is critical to the design of rational cell therapy approaches. In this review, we will discuss the key molecular mechanisms that govern the homing of MSC to bone marrow, the mobilization of MSC to tumors and injured sites via circulation, and strategies that enhance MSC migration...
2013: Histology and Histopathology
Marion K Mateos, Tracey A O'Brien, Cecilia Oswald, Melissa Gabriel, David S Ziegler, Richard J Cohn, Susan J Russell, Draga Barbaric, Glenn M Marshall, Toby N Trahair
BACKGROUND: Over the last 25 years, donor source, conditioning, graft-versus-host disease prevention and supportive care for children undergoing hematopoeitic stem cell transplantation (HSCT) have changed dramatically. HSCT indications for acute lymphoblastic leukemia (ALL) now include high-risk patients in first and subsequent remission. There is a large burden of infectious and pre-HSCT morbidities, due to myelosuppressive therapy required for remission induction. We hypothesized that, despite these trends, overall survival (OS) had increased...
September 2013: Pediatric Blood & Cancer
Hala Moukhachen, Prabalini Rajendram, Sanjay Chawla, Nina Raoof, Kaye Hale, Louis Voigt, Stephen Pastores, Neil Halpern
SESSION TYPE: Cardiovascular Case Report PostersPRESENTED ON: Tuesday, October 23, 2012 at 01:30 PM - 02:30 PMINTRODUCTION: Pulmonary veno-occlusive disease (PVOD) is an uncommon variant of primary pulmonary artery hypertension (PAH) and is a rare but fatal complication of hematopoeitic stem cell transplant (HSCT). It often goes unrecognized antemortem.CASE PRESENTATION: 63-year-old man with history of Burkitt's lymphoma s/p chemotherapy in 2003 followed by autologous HSCT in 2005. In January 2011, he was diagnosed with MDS and received chemotherapy followed by an allogeneic HSCT...
October 1, 2012: Chest
Xueying Wang, Baojie Li
Bone remodeling is carried out by bone marrow mesenchymal stem cell derived osteoblasts, which form the bones, and hematopoeitic stem cell derived osteoclasts, which absorb the bones. Their actions are coordinated in two ways: osteoblasts and their precursors synthesize and secrete cytokines such as RANKL and M-CSF to regulate osteoclastogenesis; bone resorption releases matrix associated TGF-β and BMPs to stimulate bone formation at the same sites. Recent studies on transgenic mouse models revealed that several proteins involved in the DNA damage response play important roles in bone remodeling...
December 2007: International Journal of Biomedical Science: IJBS
Liesbet Lieben, Geert Carmeliet
The active form of vitamin D [1,25(OH)2D] is an important regulator of calcium and bone homeostasis, as evidenced by the consequences of 1,25(OH)2D inactivity in man and mice, which include hypocalcemia, hypophosphatemia, secondary hyperparathyroidism and bone abnormalities. The recent generation of tissue-specific (intestine, osteoblast/osteocyte, chondrocyte) vitamin D receptor (Vdr) null mice has provided mechanistic insight in the cell-specific actions of 1,25(OH)2D and their contribution to the integrative physiology of VDR signaling that controls bone and mineral metabolism...
June 2013: Bone
Bo K Mortensen, Søren L Petersen, Brian Kornblit, Per K Andersen, Peter Braendstrup, Niels S Andersen, Henrik Sengeløv, Lars Vindeløv
Non-myeloablative conditioning hematopoietic cell transplantation (NMC-HCT) has improved the treatment of chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). In a cohort of 85 patients (45 with CLL and 40 with FL), we observed 5-yr overall survival (OS) and progression-free survival (PFS) of 53% and 38% in the CLL group and 81% and 76% in the FL group. In the both the CLL group and the FL group, a strong trend toward better OS and PFS was observed among patients in complete remission (CR) at HCT...
August 2012: European Journal of Haematology
Karin Golan, Yaron Vagima, Aya Ludin, Tomer Itkin, Shiri Cohen-Gur, Alexander Kalinkovich, Orit Kollet, Chihwa Kim, Amir Schajnovitz, Yossi Ovadya, Kfir Lapid, Shoham Shivtiel, Andrew J Morris, Mariusz Z Ratajczak, Tsvee Lapidot
The mechanisms of hematopoietic progenitor cell egress and clinical mobilization are not fully understood. Herein, we report that in vivo desensitization of Sphingosine-1-phosphate (S1P) receptors by FTY720 as well as disruption of S1P gradient toward the blood, reduced steady state egress of immature progenitors and primitive Sca-1(+)/c-Kit(+)/Lin(-) (SKL) cells via inhibition of SDF-1 release. Administration of AMD3100 or G-CSF to mice with deficiencies in either S1P production or its receptor S1P(1), or pretreated with FTY720, also resulted in reduced stem and progenitor cell mobilization...
March 15, 2012: Blood
Ruby Khoury, Miguel R Abboud
Sickle cell disease (SCD) is associated with significant morbidity, a decreased lifespan and a poor quality of life. While there is increasing evidence that hydroxyurea can improve the course of severe SCD, hematopoeitic stem-cell transplantation (HSCT) remains the only curative option for SCD. Multicenter trials have shown that HSCT after myeloablative conditioning has excellent outcomes in children with SCD, with an overall survival ranging from 93 to 97% and an event-free survival between 82 and 86%. With better understanding of the course of SCD in adulthood, there has been increasing interest in making HSCT a viable intervention in adults...
June 2011: Expert Review of Hematology
Megan M Multhaup, Sweta Gurram, Kelly M Podetz-Pedersen, Andrea D Karlen, Debra L Swanson, Nikunj V Somia, Perry B Hackett, Morton J Cowan, R Scott McIvor
Artemis is an endonucleolytic enzyme involved in nonhomologous double-strand break repair and V(D)J recombination. Deficiency of Artemis results in a B- T- radiosensitive severe combined immunodeficiency, which may potentially be treatable by Artemis gene transfer into hematopoietic stem cells. However, we recently found that overexpression of Artemis after lentiviral transduction resulted in global DNA damage and increased apoptosis. These results imply the necessity of effecting natural levels of Artemis expression, so we isolated a 1 kilobase DNA sequence upstream of the human Artemis gene to recover and characterize the Artemis promoter (APro)...
October 2011: DNA and Cell Biology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"